Administration of the dual GLP-1/GIP receptor agonist tirzepatide has been reported to improve hepatic fibrosis, the NAFLD activity score, and its individual components, including steatosis, lobular inflammation, and hepatocyte ballooning [30]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.